

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 1. (Currently amended) A method of diagnosing or predicting susceptibility
2 to a clinical subtype of Crohn's disease characterized by fibrostenosing disease **independent of**
3 **small bowel involvement**, said method comprising:
4 **determining the presence or absence in an individual** (a) genotyping an
5 individual for the presence or absence of a fibrostenosis-predisposing the SNP 13 allele in the
6 NOD2/CARD15 gene using enzymatic amplification of nucleic acid from said individual,
7 wherein said **fibrostenosis-predisposing SNP 13** allele is an insertion of a G at position 248 of
8 SEQ ID NO:5 or an insertion of a C at position 294 of SEQ ID NO:6; and (SNP 13),
9 **wherein (b) indicating that** the presence of said **fibrostenosis-predisposing SNP**
10 **13** allele is diagnostic of or predictive of susceptibility to the clinical subtype of Crohn's disease
11 characterized by fibrostenosing disease **independent of small bowel involvement**.

1 2. (Canceled)

1 3. (Canceled)

1 4. (Currently amended) The method of claim 1, wherein NF-kappa B
2 activation by a NOD2/CARD15 polypeptide encoded by said **fibrostenosis-predisposing SNP**
3 **13** allele is reduced as compared to NF-kappa B activation by a wild-type NOD2/CARD15
4 polypeptide.

1 5. (Canceled)

1 6. (Canceled)

1 7. (Canceled)

1 8. (Canceled)

1 9. (Canceled)

1 10. (Canceled)

1 11. (Canceled)

1 12. (Canceled)

1 13. (Canceled)

1 14. (Canceled)

1 15. (Canceled)

1 16. (Currently amended) The method of claim 1, wherein said ~~fibrostenosis-~~
2 ~~predisposing~~ SNP 13 allele is associated with said clinical subtype of Crohn's disease
3 characterized by fibrostenosing disease ~~independent of small bowel involvement~~ with an odds
4 ratio of at least 2 and a lower 95% confidence limit greater than 1.

1 17. (Currently amended) The method of claim 1, further comprising
2 generating a report indicating the presence or absence in said individual of said ~~fibrostenosis-~~
3 ~~predisposing~~ SNP 13 allele.

1 18. (Currently amended) The method of claim 1, further comprising
2 generating a report indicating the presence or absence in said individual of said clinical subtype
3 of Crohn's disease characterized by fibrostenosing disease ~~independent of small bowel~~
4 ~~involvement~~.

1 19. (Canceled)

1 20. (Currently amended) The method of claim ~~[[19]]~~ 1, wherein said
2 amplification is polymerase chain reaction amplification.

1 21. (Original) The method of claim 20, wherein said polymerase chain
2 reaction amplification is performed using one or more fluorescently labeled probes.

1 22. (Previously presented) The method of claim 20, wherein said polymerase
2 chain reaction amplification is performed using one or more probes comprising a DNA minor
3 groove binder.

1 23. (Currently amended) A method of optimizing therapy in an individual,
2 said method comprising:

3 (a) ~~determining the presence or absence in said individual~~ genotyping an
4 individual for the presence or absence of a fibrostenosis-predisposing the SNP 13 allele in the
5 NOD2/CARD15 gene using enzymatic amplification of nucleic acid from said individual,
6 wherein said ~~fibrostenosis-predisposing~~ SNP 13 allele is an insertion of a G at position 248 of
7 SEQ ID NO:5 or an insertion of a C at position 294 of SEQ ID NO:6; ~~(SNP-13)~~,

8 (b) diagnosing individuals in which said ~~fibrostenosis-predisposing~~ SNP 13
9 allele is present as having a fibrostenosing subtype of Crohn's disease; ~~[[,]]~~ and

10 (c) treating said individual having a fibrostenosing subtype of Crohn's disease
11 based on said diagnosis.

1 24. (Currently amended) The method of claim 23, wherein said
2 ~~fibrostenosis-predisposing~~ SNP 13 allele is associated with said clinical subtype of Crohn's
3 disease characterized by fibrostenosing disease ~~independent of small bowel involvement~~ with
4 an odds ratio of at least 2 and a lower 95% confidence limit greater than 1.

1 25. (Currently amended) The method of claim 23, further comprising
2 generating a report indicating the presence or absence in said individual of said ~~fibrostenosis-~~
3 ~~predisposing~~ SNP 13 allele.

1 26. (Currently amended) The method of claim 23, further comprising
2 generating a report indicating the presence or absence in said individual of said clinical subtype
3 of Crohn's disease characterized by fibrostenosing disease **independent of small bowel**
4 **involvement.**

1 27. (Canceled)

1 28. (Currently amended) The method of claim ~~[[27]]~~ **23**, wherein said
2 amplification is polymerase chain reaction amplification.

1 29. (Previously presented) The method of claim 28, wherein said polymerase
2 chain reaction amplification is performed using one or more fluorescently labeled probes.

1 30. (Previously presented) The method of claim 28, wherein said polymerase
2 chain reaction amplification is performed using one or more probes comprising a DNA minor
3 groove binder.